Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market Is Supporting Development Across The Biosimilar Interleukins Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Biosimilar Interleukins Market By 2030?

The biosimilar interleukins market has shown significant expansion in recent years. It is projected to expand from $7.52 billion in 2025 to $10.54 billion in 2026, at a compound annual growth rate (CAGR) of 40.2%. The growth during previous periods is attributable to the elevated cost of originator interleukin biologics, the rising prevalence of autoimmune and inflammatory diseases, the increasing burden of rheumatoid arthritis and psoriasis, restricted patient access to biologic therapies, and enhanced awareness of biologics in immune modulation.

The biosimilar interleukins market size is anticipated to undergo significant expansion in the near future, with projections showing it will reach **$41.22 billion in 2030, at a compound annual growth rate (CAGR) of 40.6%.** This growth during the forecast period can be attributed to the expiration of patents for branded interleukins, the expanding pipelines for biosimilar clinical trials, increasing physician acceptance of biosimilars, government policies that support biosimilar use, and a rising demand for affordable biologic treatments for cancer and immunology. Key trends expected in this period include the increased adoption of biosimilar interleukins in treating autoimmune diseases, a growing demand for cost-effective alternatives to originator biologics, an expansion of biosimilar approvals across multiple indications, the increasing utilization of interleukins in chronic inflammatory disorders, and the strengthening of regulatory frameworks that foster biosimilar adoption.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Which Major Factors Are Contributing To The Development Of The Biosimilar Interleukins Market?

The rising occurrence of autoimmune conditions like psoriasis and rheumatoid arthritis is projected to boost the expansion of the interleukin biosimilars market throughout the forecast period. Autoimmune disorders are conditions where the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs, such as anti-interleukin antibodies, have exhibited significant clinical benefits in regulating cells and in directing their proliferation, activation, and migration. For instance, in February 2024, reports published by the National Institutes of Health (NIH), a US-based biomedical research agency, indicated that the estimated annual increases in the global incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively. Therefore, the escalating prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

Which Segment-Based Categories Are Covered In The Biosimilar Interleukins Market?

The biosimilar interleukins market covered in this report is segmented –

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:

1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management

2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment

3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders

4) By IL-5: Asthma Treatment, Eosinophilic Disorders

5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

Which Trends Are Supporting The Evolution Of The Biosimilar Interleukins Market?

Prominent companies operating in the biosimilar interleukins market are innovating new products, such as Tofidence (tocilizumab-bavi), to boost their profitability in the market. Tofidence functions as a monoclonal antibody designed to target and bind to interleukin-6 receptors, used in the treatment of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen Inc., a US-based biotechnology company, received approval from the FDA for Tofidence (tocilizumab-bavi) as the first biosimilar referencing Genentech’s Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has been approved for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Who Are The Major Companies Operating In The Biosimilar Interleukins Market?

Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

Access The Complete Biosimilar Interleukins Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Which Region Accounts For The Highest Share Of The Biosimilar Interleukins Market?

North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biosimilar Interleukins Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Browse Through More Reports Similar to the Global Biosimilar Interleukins Market 2026, By The Business Research Company

Generic Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795